Answers are grounded in this paper and cite their sources.
Raloxifene, a selective estrogen receptor modulator (SERM) used to treat osteoporosis and prevent breast cancer, has been detected in aquatic environments, raising concerns about its environmental fate and ecological effects. This study investigated raloxifene photodegradation in different aqueous matrices, evaluating the influence of water matrix composition, pH, and humic acid. Photodegradation kinetics were monitored under irradiation, and transformation products were characterized using liquid chromatography coupled with high-resolution mass spectrometry (LC–HRMS). The potential endocrine-disrupting effects and aquatic toxicity of raloxifene and its transformation products were assessed using in silico prediction tools. Photodegradation was strongly dependent on environmental conditions. In ultrapure water, raloxifene was relatively photostable, whereas in river water, 96.8% was degraded within 4 h of irradiation. A total of nine phototransformation products were identified for the first time. Accurate mass measurements and fragmentation analysis supported the proposed transformation pathways with dimerization identified as the predominant transformation pathway. The toxicological predictions generally indicated reduced endocrine-disrupting potential and aquatic toxicity following phototransformation. However, selected dimeric photoproducts exhibited increased predicted toxicity toward some aquatic organisms, indicating that photochemical transformation does not necessarily eliminate environmental hazards. These findings provide new insights into the environmental fate and ecological risk of raloxifene in aquatic environments.
No takes yet. Share an insight, caveat, or question.
Trawiński et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: